🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  2. Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  3. Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  4. Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  5. Mycophenolate Mofetil

    BRIGHT MINDS BIOSCIENCES INC.

    Hematopoietic Stem Cell Transplantation

    phase 1 small molecule active

    1 trial

  6. N-acetyl cysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  7. NBI-6024

    NEUROCRINE BIOSCIENCES INC

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  8. NBI-77860

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 1 small molecule terminated

    1 trial

  9. NBI-98854 50 mg capsule

    NEUROCRINE BIOSCIENCES INC

    Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

    phase 1 small molecule completed

    1 trial

  10. NBI-98854 50 mg capsule once daily

    NEUROCRINE BIOSCIENCES INC

    Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

    phase 1 small molecule completed

    1 trial

  11. ND-003 40mg

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule active

    1 trial

  12. NDX-1017

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  13. NP-G2-044

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  14. NP101

    Teva Pharma GmbH

    Compare Bioequivalence Patches Previously Used in the NP101-007 Study

    phase 1 small molecule completed

    1 trial

  15. NRS-033

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. NT-301 1 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tolerability of NT-301 Nasal Spray

    phase 1 other completed

    1 trial

  17. NX210c

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Elderly

    phase 1 small molecule completed

    1 trial

  18. NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

    Chongqing Precision Biotech Co., Ltd

    Bone Sarcoma

    phase 1 mab active

    1 trial

  19. Nafamostat Mesilate

    BRIGHT MINDS BIOSCIENCES INC.

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  20. Nalmefene

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 1 small molecule completed

    1 trial

  21. Naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Overdose

    phase 1 small molecule completed

    1 trial

  22. Naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 1 small molecule completed

    1 trial

  23. Naloxone Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 1 small molecule terminated

    1 trial

  24. Naltrexone and Bupropion SR

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources